# a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia

> **NCT07140809** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **BIOLOGICAL:** JMT202 injection
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07140809
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-09
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-10-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07140809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07140809, "a Phase 1b/2a Study of JMT202 Injection in Participants With Hypertriglyceridemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07140809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*